BMS-103

• Description:

  BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM) . BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer[1].

• UNSPSC:

  12352005

• Target:

  PD-1/PD-L1

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer

• Smiles:

  CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3

• Molecular Formula:

  C25H29NO4

• Molecular Weight:

  407.50

• References & Citations:

  [1]anesan A, et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep. 2019 Aug 27;9 (1) :12392. d

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1675202-86-4]